However, Novo Nordisk is expected to emerge as the leading company, having a large portfolio of GLP1 drugs, and is expected to capture 55 per cent of the market share in 2029.
Patients should explore their coverage options and discuss affordability with their healthcare provider before starting treatment
Ambitious protocols integrate direct measurements: Electrophysiology LTP (Long-Term Potentiation) hippocampal on CA1 slices, gold standard of synaptic plasticity
Insurance companies, including Anthem BCBS, are more likely to cover Wegovy when it is intended for one of the above mentioned FDA-approved conditions
While designing treatment strategies aimed at improving stroke recovery, greater attention should be paid to non-neuronal cells which are able to produce substantial amounts of BDNF after ischemic stroke
Because of this overlap, taking them together doesnt lead to better or faster weight loss